CALGARY, AB, May 10, 2021 /PRNewswire/ -
FluroTech Ltd. (TSXV: TEST) (OTCQB: FLURF) and wholly owned subsidiary FluroTest or The Company), a diagnostics technology leader in high output rapid antigen testing for the detection of SARS-CoV-2 and other pathogens, today announces the next phase of its ongoing clinical trials with its trial partner Toolbox Medical Innovations ( Toolbox ).
The Company is pleased to report that approximately 600 volunteer participants, including both symptomatic and asymptomatic individuals, are being identified from six clinical site locations across California, Texas, Colorado, Rhode Island and Florida (with two sites) to determine performance detection results alongside a comparator RT-PCR assay. The data collected from this and the upcoming pilot program with California-based Total Testing Solutions (previously announced in the Company s news release dated May 3, 2021) will be used to support submissions for Emergency Use Authorization ( EUA
FluroTech and FluroTest Announce Definitive Amalgamation Agreement
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
FluroTech and FluroTest Announce Definitive Amalgamation Agreement FluroTech Shareholders to Control 100% of Pandemic Defense Testing System
leaderpost.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from leaderpost.com Daily Mail and Mail on Sunday newspapers.
MRIGlobal to Perform Work On DARPA DIGET Program
DARPA s Biological Technologies Office recently made awards for Detect It with Gene Editing Technologies (DIGET)
News provided by
Share this article
Share this article
KANSAS CITY, Mo., Jan. 14, 2021 /PRNewswire/ The Defense Advanced Research Projects Agency (DARPA) funds innovative breakthrough and emerging technologies for the Department of Defense (DOD). Developing and implementing cutting edge technology that is high risk and reward requires the most advanced multidisciplinary teams. DARPA s Biological Technologies Office recently awarded the MRIGlobal Team s proposal to Detect It with Gene Editing Technologies (DIGET).
DIGET aims to provide next-generation detection for the DOD by combining gene-editing technology with fieldable diagnostics and biosurveillance. DIGET will apply CRISPR technologies to develop a disposable point of care device for detection of at least 10 targets and a massively multiplexed device for at